合成工艺路线中心备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目整合推广和市场调研服务, 请致函联系我们
数据库发展方向
1. 智能化融合：发展数据挖掘、集成、分析、可视化及人工智能工具，实现数据与文献、模型、计算等资源的有机融合，促进领域数智驱动科研新范式变革.
2. 标准化体系建设：以统一的数据标准管理体系为基础，系统整合全链条多源异构数据，聚焦高价值业务需求，精准构建结构合理、标注规范、语义清晰的数据资源.
3. 开放共享生态：开展数据提供方、使用方和服务方生态体系建设，实现多元主体间数据共享、共用、共治。.
4. 多模态数据处理：构建“全模态数据治理平台+高质量数据服务”一体化解决方案，提升非结构化数据处理能力.
客户展示
合成工艺路线中心
Vipivotide tetraxetan CAS# 1702967-37-0
Vipivotide tetraxetan (^177Lu-PSMA-617) is a radioligand targeting prostate-specific membrane antigen (PSMA) for selective delivery of β-emitting lutetium-177 to prostate cancer cells. In preclinical ...
Reference: Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancerAssignees: Bayer AS; Bayer Aktiengesellschaft Inventors: Cuthbertson, Alan; Boehnke, NielsWorld Intellectual Property OrganizationPatent Number WO2021013978
Avapritinib CAS# 1703793-34-3 阿泊替尼
Avapritinib is a selective, orally available small-molecule inhibitor of KIT and PDGFRA receptor tyrosine kinases, with strongest activity against PDGFRA exon 18 mutations, including the D842V substit...
CN110950872
Aprepitant CAS# 170729-80-3 阿瑞吡坦
Aprepitant is a small molecule, high-affinity substance P antagonist (SPA) with antiemetic activity. Crossing the blood brain barrier, aprepitant binds selectively to the human substance P/neurokinin ...
Brands, Karel M. J.; Payack, Joseph F.; Rosen, Jonathan D.; Nelson, Todd D.; Candelario, Alexander; Huffman, Mark A.; Zhao, Matthew M.; Li, Jing; Craig, Bridgette; Song, Zhiguo J.; Tschaen, David M.; Hansen, Karl; Devine, Paul N.; Pye, Philip J.; Rossen, Kai; Dormer, Peter G.; Reamer, Robert A.; Welch, Christopher J.; Mathre, David J.; Tsou, Nancy N.; McNamara, James M.; Reider, Paul J.Efficient Synthesis of NK1 Receptor Antagonist Aprepitant Using a Crystallization-Induced Diastereoselective Transformation. Journal of the American Chemical Society. Volume 125. Issue 8. Pages 2129-2135. 2003.
Sepiapterin CAS# 17094-01-8 墨蝶呤
Sepiapterin is a natural precursor of tetrahydrobiopterin (BH4), a critical cofactor for nitric oxide synthases and aromatic amino acid hydroxylases. In vitro, sepiapterin restores intracellular BH4 a...
Patent#: WO2013168693
Aliskiren CAS# 173334-58-2 阿利克仑半富马酸盐
Aliskiren is a direct renin inhibitor. Its indication is essential (primary) hypertension.
A convergent synthesis of the renin inhibitor CGP60536B; Sandham, D. A.; Taylor, R. J.; Carey, J. S.; Fassler, A.; Tetrahedron Letters; Volume 41; Issue 51; Pages 10091-10094; Journal; 2000
Atrasentan CAS# 173937-91-2 (2R,3R,4S)-4-(1,3-苯并二氧戊环-5-基)-1-[2-(二丁基氨基)-2-氧代乙基]-2-(4-甲氧基苯基)吡咯烷-3-羧酸
Atrasentan is a selective endothelin-A (ET_A) receptor antagonist developed primarily for cardiovascular and renal indications, particularly diabetic nephropathy and prostate cancer. In preclinical st...
Organocatalytic enantioselective conjugate addition of nitromethane to benzylidene-2-benzoyl acetate: asymmetric synthesis of ABT - 627, an endothelin receptor antagonistBy: Hajra, Saumen; et alFrontiers in Chemistry (Lausanne, Switzerland) (2020), 8, 135
Maribavir CAS# 176161-24-3 BENZIMIDAVIR 苯并咪唑核苷
Maribavir, also known as 1263W-94; BW-1263W-94; GW-1263; GW-257406X; SHP-620; VP-41263; BW-1263W94, is an UL97 kinase inhibitor potentially for the treatment of cytomegalovirus (CMV) infection. The me...
Patent#: WO2024081308
Abametapir CAS# 1762-34-1 5 5'-二甲基-2,2'-联吡啶
Abametapir, a metalloproteinase inhibitor, demonstrated potent pediculicidal activity in preclinical studies. In vitro assays showed abametapir lotion (0.74–1% w/v) achieved >95% mortality of Pediculu...
Reference:High-yield synthesis of 5,5'-dimethyl-2,2'-bipyridine and 5,5''-dimethyl-2,2':6',2''-terpyridine and some bifunctionalization reactions using N-bromosuccinimide. By: Schubert, Ulrich S.; et al, Synthesis (1999), (5), 779-782
Ambrisentan CAS# 177036-94-1 安倍生坦
Ambrisentan, also known as BSF-208075 and LU-208075, is a drug indicated for use in the treatment of pulmonary hypertension. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagon...
Isolation, identification, characterization, synthesis and quality control strategy of new process-related impurities in ambrisentan; Feng, Wei-Dong; Zhuo, Song-Ming; Zhang, Fu-Li Journal of Pharmaceutical and Biomedical Analysis Volume 165 Pages 325-337 Journal; 2019
Remibrutinib CAS# 1787294-07-8
Remibrutinib (LOU064) is a highly selective, covalent Bruton’s tyrosine kinase (BTK) inhibitor developed by Novartis for autoimmune and inflammatory disorders. In vitro, Remibrutinib exhibits potent i...
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine KinaseBy: Angst, Daniela; et alJournal of Medicinal Chemistry (2020), 63(10), 5102-5118
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
